KDM4A and leukemia: Hence, we demonstrated KDM4i sensitisation of leukaemia cells to inhibitors of DNA damage pathways such as poly-ADP ribose polymerase (PARP) inhibitor, olaparib, suggesting future clinical evaluation of KDM4A and other key components in DNA damage/response signalling pathways as potential therapeutic vulnerabilities in AML.